Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is epithelioid sarcoma?
Epithelioid sarcoma is a rare soft-tissue sarcoma that tends to occur in adolescents and younger adults. A sarcoma is a cancer of the body's connective tissues; epithelioid sarcoma is unusual in that its cells look somewhat like the cells that line surfaces (epithelial cells), which can make it tricky to diagnose. The 'classic' (distal) form most often begins on a hand, finger, forearm, or lower leg as one or more firm, slowly growing nodules in or just under the skin; because these can ulcerate or look like a non-healing sore or a wart, the diagnosis is sometimes delayed. A less common 'proximal' form arises in the trunk, pelvis, or groin, tends to be more aggressive, and occurs in somewhat older adults. Epithelioid sarcoma usually grows slowly, but it has two behaviors that shape treatment: it tends to creep along tendons, nerves, and fascial planes, spreading microscopically beyond the visible nodule and often producing new nodules nearby; and, unlike most soft-tissue sarcomas, it can spread to nearby lymph nodes as well as to the lungs. At the molecular level, the great majority of epithelioid sarcomas have lost a protein called INI1 (SMARCB1), and detecting this loss helps confirm the diagnosis and has opened a targeted treatment option. The cornerstone of treatment is complete surgical removal with wide margins, because of the tumor's tendency to track along tissue planes. Radiation is commonly combined with surgery to treat the microscopic disease that extends beyond what can be removed, lowering the chance of local recurrence and helping preserve the hand or limb. Because the tumor can travel to lymph nodes, the team also evaluates and watches the regional nodes. For advanced or inoperable disease, a newer targeted pill (an EZH2 inhibitor) that exploits the INI1 loss is now an option.
The main types
Doctors group epithelioid sarcoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Classic (distal) epithelioid sarcoma | The more common form — firm nodules on a hand, finger, forearm, or lower leg in a younger person; slow-growing but prone to local spread along tissue planes, so it is treated with wide surgery and often radiation. |
| Proximal-type epithelioid sarcoma | A less common, more aggressive form arising in the trunk, pelvis, or groin of somewhat older adults; treated more intensively because of its higher risk of spread. |
| Node-involving epithelioid sarcoma | Because this tumor can spread to nearby lymph nodes (unusual for sarcomas), the regional nodes are evaluated and, if involved, addressed with surgery and/or radiation. |
| Advanced / inoperable epithelioid sarcoma | Disease that can't be fully removed or has spread; now treatable with a targeted pill (an EZH2 inhibitor) that takes advantage of the tumor's characteristic INI1 loss, alongside radiation for symptom control. |
Staging, in plain terms
Epithelioid sarcoma is staged with the soft-tissue sarcoma TNM system, but it has one feature that sets it apart from most sarcomas: it can spread to nearby lymph nodes, so the N category and examination of the regional nodes carry more importance here than for the typical soft-tissue sarcoma. The T category reflects the size and depth of the tumor, the M category notes distant spread (most often to the lungs), and the grade describes how aggressive the cells look. The diagnosis is confirmed not by stage but by pathology: epithelioid sarcoma can mimic both benign conditions and other cancers, and the key clue is loss of the INI1 (SMARCB1) protein in the tumor cells, found in the large majority of cases. That same loss is what a targeted drug now exploits in advanced disease. Beyond the formal stage, the behavior that most shapes treatment is the tumor's tendency to track microscopically along tendons, nerves, and fascial planes and to produce new nodules nearby — which means the surgery and radiation must cover more than just the visible mass, and the team must watch for both local recurrence and lymph-node spread. In practice, the questions that guide care are the size and location of the tumor, how far it has tracked along tissue planes, whether nearby lymph nodes are involved, and whether it has spread to the lungs.
| Soft-tissue sarcoma TNM with grade — tumor size and depth (T), lymph nodes (N), distant spread (M), and grade; loss of the INI1/SMARCB1 protein confirms the diagnosis | What it generally means |
|---|---|
| Localized, small | A nodule confined to its site of origin; treated with wide surgery and often radiation, with attention to the nearby lymph nodes. |
| Localized with local spread along tissue planes | A tumor that has tracked along tendons or fascia or produced nearby nodules; treated with more extensive surgery and radiation to cover the microscopic disease. |
| Regional (lymph node) spread | Cancer that has reached nearby lymph nodes — uncommon for sarcomas but seen here; treated with surgery to the nodes and/or radiation, in addition to the primary tumor. |
| Metastatic (lungs or beyond) | Cancer that has spread to distant sites such as the lungs; treated with systemic therapy including the targeted EZH2 inhibitor, with radiation for symptom control or limited deposits. |
The standard of care
Epithelioid Sarcoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Wide surgical removal
Removing the tumor with generous margins is the central treatment; because epithelioid sarcoma tracks along tendons and tissue planes, the operation aims to capture microscopic disease well beyond the visible nodule.
Radiation therapy (with surgery)
Commonly combined with surgery to treat the microscopic disease that extends along tissue planes; it lowers the chance of local recurrence and can help preserve the hand or limb when wide surgery alone would be disfiguring.
Lymph-node evaluation
Because this tumor can spread to nearby lymph nodes, the regional nodes are examined and imaged, and addressed with surgery and/or radiation if involved — a step that matters more here than for most sarcomas.
Targeted therapy for advanced disease
An EZH2-inhibitor pill (tazemetostat), which takes advantage of the tumor's characteristic INI1 loss, is approved for epithelioid sarcoma that can't be removed or has spread.
Sarcoma specialty center care
Treatment at a center with a dedicated sarcoma team gives the best chance of an accurate diagnosis, a complete first operation, appropriate radiation, and access to targeted therapy and clinical trials.
How radiation treatment works
Radiation therapy treats epithelioid sarcoma by delivering focused beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. Radiation is a natural partner to surgery here because of the way this tumor grows: rather than staying within a single, well-defined nodule, epithelioid sarcoma creeps microscopically along tendons, nerves, and fascial planes and tends to produce new nodules nearby. Removing only the visible nodule risks leaving behind those microscopic extensions, which then seed a local recurrence. Radiation treats a wider zone — designed to follow the tissue planes the tumor travels along — sterilizing that microscopic disease so the cancer is less likely to come back and so a hand, finger, or limb can be preserved when wide surgery alone would be disfiguring. This is particularly valuable because the classic form so often occurs in the small, functionally important structures of a hand or forearm in a young person. Radiation can be given before or after surgery: beforehand it uses a smaller field and a lower dose and can make a function-preserving operation more achievable, though it requires extra attention to wound healing; afterward it treats the tumor bed and the path of microscopic spread at a higher dose over a larger area. Because the target is often elongated to follow tissue planes, techniques such as intensity-modulated radiation shape the dose tightly around that irregular volume while sparing the delicate surrounding structures. Epithelioid sarcoma is also one of the few sarcomas that can spread to nearby lymph nodes, so radiation may be directed at the regional nodes when they are involved or at risk. For advanced disease, radiation is used to control symptoms or treat a limited number of deposits, while the targeted EZH2-inhibitor pill works throughout the body by exploiting the tumor's characteristic INI1 loss. Across these settings, radiation's strength is treating disease that extends beyond the reach of the scalpel — the central challenge of this slow but stubbornly infiltrative cancer.
The main ways radiation is delivered for epithelioid sarcoma:
Preoperative (neoadjuvant) radiation
Radiation given before surgery treats the microscopic disease tracking along tissue planes using a smaller field and lower dose, which can make a function-preserving operation more achievable, at the cost of more wound-healing care.
Postoperative (adjuvant) radiation
Radiation to the tumor bed and the path of microscopic spread after surgery, used when preoperative radiation wasn't given, lowers the chance of local recurrence, at a higher dose over a larger area.
Intensity-modulated radiation (IMRT)
Shaping the beams tightly around an often-elongated target spares surrounding tendons, bone, and the small structures of a hand or foot, helping preserve function in these delicate locations.
Radiation to lymph nodes
When nearby lymph nodes are involved or at risk — a possibility unique to this and a few sarcomas — radiation can treat the nodal area along with, or instead of, surgery to the nodes.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Targeted EZH2 inhibitor approved for epithelioid sarcoma: Tazemetostat, an oral EZH2 inhibitor that exploits the tumor's loss of the INI1/SMARCB1 protein, became the first targeted therapy approved for advanced or inoperable epithelioid sarcoma, giving patients a new systemic option beyond chemotherapy.[1]
Tazemetostat epithelioid sarcoma approval trial
Surgery plus radiation for local control: Because epithelioid sarcoma tracks along tissue planes and recurs locally, series support combining wide surgery with radiation to treat microscopic disease and preserve function, especially for tumors of the hand and limb.[2]
Epithelioid sarcoma local-control studies
Lymph-node spread distinguishes epithelioid sarcoma: Unlike most soft-tissue sarcomas, epithelioid sarcoma can spread to regional lymph nodes; studies emphasize evaluating and, when involved, treating the nodes with surgery and/or radiation as part of comprehensive care.[3]
Epithelioid sarcoma nodal-involvement studies
Common questions
My nodule grew slowly and looked harmless — why is it cancer? Epithelioid sarcoma is known for being slow-growing and for looking deceptively benign — it can resemble a wart, a cyst, a callus, or a non-healing sore, and it sometimes ulcerates. That appearance, combined with its rarity, is why the diagnosis is sometimes delayed. But it is a true cancer that can spread along tissue planes, to nearby lymph nodes, and to the lungs. The key to diagnosis is expert pathology, including a test that detects loss of the INI1 (SMARCB1) protein, which is present in the large majority of these tumors. If you have a firm, persistent, or ulcerating nodule on a hand, forearm, or lower leg that isn't healing, it deserves evaluation and, if needed, a biopsy at a sarcoma center.
Why does the team check my lymph nodes? Most soft-tissue sarcomas rarely spread to lymph nodes, but epithelioid sarcoma is one of the exceptions — it can travel to the nodes near the tumor. Because of this, the team examines and images the regional lymph nodes as part of staging, and if any are involved they are addressed with surgery and/or radiation along with treatment of the primary tumor. Watching the nodes is an important part of comprehensive care for this particular sarcoma and is one of the ways it differs from most others.
What is the new targeted pill I've heard about? The great majority of epithelioid sarcomas have lost a protein called INI1 (SMARCB1), and that loss makes the tumor cells dependent on a related protein called EZH2. A pill called tazemetostat blocks EZH2 and is approved for epithelioid sarcoma that can't be surgically removed or has spread. It offers a targeted option beyond chemotherapy for advanced disease. It does not replace surgery and radiation, which remain the main treatments for tumors that can be removed, but it is an important addition for advanced cases — and a good example of how understanding a tumor's specific genetics opens new treatments.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.